News from NORD

CORD Offers Consensus Framework for Ethical Collaboration

Publish date: February 17, 2017

 

The Canadian Organization for Rare Disorders (CORD) has developed a Consensus Framework to encourage ethical collaboration among patient organizations, health care professionals, and the pharmaceutical industry.

Recommended Reading

PERSIST-2 might allay some concerns about pacritinib in myelofibrosis
MDedge Hematology and Oncology
VIDEO: Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease
MDedge Hematology and Oncology
Join Others Around the World in Observing Rare Disease Day
MDedge Hematology and Oncology
AWaRDS Study Examines Services for Adults With Rare Disorders
MDedge Hematology and Oncology
NORD Report Shows Majority of States Fall Short on Reducing Burden of Living With a Rare Disease
MDedge Hematology and Oncology
Nivolumab safe, effective for salvage in advanced gastric cancer
MDedge Hematology and Oncology
NORD Seeks Input Regarding Patient Protections and ACA
MDedge Hematology and Oncology
Rare Disease Day 2017 Will Highlight Research Theme
MDedge Hematology and Oncology
NORD to Partner Again With Hole in the Wall Gang Camp
MDedge Hematology and Oncology
Apply Now to Join NORD’s Charity Marathon Team
MDedge Hematology and Oncology